OPHLF: AI 评分 59/100 — AI 分析 (4月 2026)

Ono Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company focused on the development, manufacturing, and marketing of innovative drugs. Their portfolio includes treatments for cancer, diabetes, and immunological diseases, with a global presence and a history dating back to 1717.

Key Facts: AI Score: 59/100 Sector: Healthcare

公司概况

概要：

Ono Pharmaceutical Co., Ltd., established in 1717, develops and markets pharmaceutical products and diagnostic reagents globally. With a diverse portfolio spanning oncology, diabetes, and immunology, the company maintains a strong presence in the healthcare sector, supported by collaborations and a robust pipeline, and currently has a market capitalization of $6.58 billion.

OPHLF是做什么的？

Ono Pharmaceutical Co., Ltd. is a global pharmaceutical company headquartered in Osaka, Japan, with a history stretching back to its founding in 1717. Initially a pharmaceutical wholesaler, the company transitioned to research and development, focusing on innovative drugs. Today, Ono Pharmaceutical develops, manufactures, and markets a wide range of pharmaceutical products and diagnostic reagents across several therapeutic areas, including oncology, diabetes, immunology, and neurology. Key products include Opdivo, an intravenous infusion for malignant tumors, and Glactiv, a tablet for type 2 diabetes. The company also offers treatments for chemotherapy-induced nausea, pheochromocytoma, and other conditions. Ono Pharmaceutical has expanded its global reach through strategic collaborations with companies like Adimab LLC, Turbine Ltd., Sibylla Biotech and academic institutions such as Harvard University. These collaborations enhance its research and development capabilities, allowing it to explore new therapeutic targets and technologies. The company's commitment to innovation and patient care has solidified its position as a key player in the pharmaceutical industry.

OPHLF的投资论点是什么？

Ono Pharmaceutical presents a compelling investment case based on its established market presence, diverse product portfolio, and strategic collaborations. With a P/E ratio of 17.79 and a profit margin of 12.3%, the company demonstrates financial stability. Growth catalysts include the expansion of existing product lines like Opdivo and Forxiga, as well as the development of new therapies in its pipeline. The company's dividend yield of 3.39% offers an attractive return for investors. However, potential risks include regulatory hurdles, competition from other pharmaceutical companies, and the inherent uncertainties of drug development. The company's beta of 0.10 suggests low volatility compared to the overall market.

OPHLF在哪个行业运营？

Ono Pharmaceutical operates within the global pharmaceutical industry, a sector characterized by intense competition, stringent regulations, and high research and development costs. The market is driven by an aging population, increasing prevalence of chronic diseases, and technological advancements in drug discovery. Ono Pharmaceutical competes with major pharmaceutical companies, including DSRLF (Daiichi Sankyo), FLMNF (Fuji Pharma), GZPHF (Guangzhou Baiyunshan Pharmaceutical), HKMPF (Lee's Pharmaceutical), and HKMPY (Hutchison Medipharma), all vying for market share in key therapeutic areas. The company's focus on innovative therapies and strategic collaborations positions it to capitalize on the growing demand for advanced medical treatments.

Drug Manufacturers - General

Healthcare

OPHLF有哪些增长机遇？

Expansion of Opdivo's Indications: Ono Pharmaceutical has the opportunity to expand the approved indications for Opdivo, its leading oncology drug. This includes pursuing approvals for new cancer types and combination therapies. The global oncology market is projected to reach $286.6 billion by 2031, providing a substantial market for Opdivo's continued growth. Timeline: Ongoing clinical trials and regulatory submissions.
Development of Novel Therapies: Ono Pharmaceutical's pipeline includes several promising drug candidates targeting various diseases, including autoimmune disorders, neurological conditions, and other cancers. Successful development and commercialization of these therapies could significantly boost revenue. The market for autoimmune disease treatments is expected to reach $150 billion by 2028. Timeline: Clinical trials in progress with potential launches in the next 3-5 years.
Strategic Collaborations and Acquisitions: Ono Pharmaceutical can pursue strategic collaborations and acquisitions to expand its product portfolio and geographic reach. Partnering with biotech companies and research institutions can accelerate drug development and access new technologies. The company's existing collaborations with Adimab LLC and Turbine Ltd. demonstrate its commitment to this strategy. Timeline: Ongoing, with potential deals announced in the next 1-2 years.
Geographic Expansion: Ono Pharmaceutical can expand its presence in emerging markets, such as China and India, where there is a growing demand for pharmaceutical products. This includes establishing local manufacturing facilities and distribution networks. The pharmaceutical market in emerging economies is expected to grow at a faster rate than developed markets. Timeline: Gradual expansion over the next 5-10 years.
Digital Health Integration: Ono Pharmaceutical can leverage digital health technologies, such as telemedicine and mobile health apps, to improve patient outcomes and enhance its market reach. This includes developing digital therapeutics and remote monitoring solutions. The digital health market is projected to reach $660 billion by 2028. Timeline: Pilot programs and partnerships in the next 2-3 years, followed by broader implementation.

Market capitalization of $6.58 billion indicates substantial company size and investor confidence.
P/E ratio of 17.79 suggests a reasonable valuation compared to earnings.
Profit margin of 12.3% demonstrates the company's ability to generate profit from its revenue.
Gross margin of 69.8% reflects efficient cost management in the production and sales of pharmaceuticals.
Dividend yield of 3.39% provides a steady income stream for investors.

OPHLF提供哪些产品和服务？

Develops and markets pharmaceutical products and diagnostic reagents.
Offers prescription drugs for oncology, diabetes, immunology, and neurology.
Conducts research and development to discover new therapeutic targets.
Manufactures pharmaceutical products in compliance with regulatory standards.
Collaborates with other companies and research institutions to accelerate drug development.
Distributes its products globally through a network of distributors and partners.
Provides patient support programs to improve adherence and outcomes.

OPHLF如何赚钱？

Develops and patents innovative pharmaceutical products.
Generates revenue through the sale of prescription drugs.
Invests in research and development to create new products.
Partners with other companies to expand its product portfolio and geographic reach.

Hospitals and clinics
Pharmacies
Patients with various medical conditions
Healthcare providers

Patented pharmaceutical products provide market exclusivity.
Strong brand reputation in key therapeutic areas.
Established relationships with healthcare providers and distributors.
Extensive research and development capabilities.

什么因素可能推动OPHLF股价上涨？

Upcoming: Clinical trial results for novel therapies in the pipeline.
Upcoming: Regulatory approvals for new indications of existing drugs.
Ongoing: Expansion of strategic collaborations and partnerships.
Ongoing: Increasing demand for pharmaceutical products in emerging markets.
Ongoing: Development of digital health solutions to improve patient outcomes.

OPHLF的主要风险是什么？

Potential: Regulatory changes and pricing pressures could impact revenue.
Potential: Competition from other pharmaceutical companies could erode market share.
Potential: Patent expirations could lead to generic competition.
Ongoing: The inherent uncertainties of drug development could result in clinical trial failures.
Ongoing: Economic downturns could reduce demand for pharmaceutical products.

OPHLF的核心优势是什么？

Innovative drug pipeline
Strong market position in Japan
Strategic collaborations with leading research institutions
Diverse product portfolio

OPHLF的劣势是什么？

Reliance on a few key products
Limited presence in some emerging markets
Exposure to generic competition
OTC listing may limit access to capital

OPHLF有哪些机遇？

Expansion into new therapeutic areas
Increased demand for pharmaceutical products in emerging markets
Development of personalized medicine
Leveraging digital health technologies

OPHLF面临哪些威胁？

Regulatory changes and pricing pressures
Competition from other pharmaceutical companies
Patent expirations
Economic downturns

OPHLF的竞争对手是谁？

Daiichi Sankyo — Global pharmaceutical company with a focus on cardiovascular and oncology drugs. — (DSRLF)
Fuji Pharma — Japanese pharmaceutical company specializing in generic drugs and women's health products. — (FLMNF)
Guangzhou Baiyunshan Pharmaceutical — Chinese pharmaceutical company with a broad range of products, including traditional Chinese medicines. — (GZPHF)
Lee's Pharmaceutical — Hong Kong-based pharmaceutical company focused on cardiovascular, dermatology, and oncology products. — (HKMPF)
Hutchison Medipharma — Chinese biopharmaceutical company developing innovative cancer therapies. — (HKMPY)

Key Metrics

MoonshotScore: 59/100

Company Profile

Headquarters: Osaka, Japan
Employees: 4,287

AI Insight

AI analysis pending for OPHLF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Ono Pharmaceutical Co., Ltd. do?

Ono Pharmaceutical Co., Ltd. is a research-driven pharmaceutical company that discovers, develops, and commercializes innovative medicines to address unmet medical needs. The company's primary focus is on prescription drugs, with a diverse portfolio spanning oncology, diabetes, immunology, and neurology. Ono Pharmaceutical generates revenue through the sale of these pharmaceutical products to hospitals, clinics, pharmacies, and healthcare providers worldwide, with a strong presence in the Japanese market and expanding global reach through strategic partnerships.

What do analysts say about OPHLF stock?

AI analysis is pending for OPHLF stock. Investors should independently research analyst ratings, price targets, and consensus estimates from various financial analysis platforms. Key valuation metrics to consider include the company's P/E ratio, profit margin, and dividend yield. Growth considerations include the company's pipeline of new drugs, expansion into emerging markets, and strategic collaborations. Investors should conduct their own due diligence before making any investment decisions.

What are the main risks for OPHLF?

Ono Pharmaceutical faces several risks inherent to the pharmaceutical industry. These include regulatory risks related to drug approvals and pricing, competition from other pharmaceutical companies, and patent expirations that could lead to generic competition. Additionally, the company faces risks associated with the inherent uncertainties of drug development, including the potential for clinical trial failures and delays. As an OTC-listed stock, OPHLF also faces risks related to lower trading volume and liquidity, as well as increased regulatory scrutiny.